Evotec SE ADR (EVO)vsNovartis AG ADR (NVS)
EVO
Evotec SE ADR
$3.11
+5.78%
HEALTHCARE · Cap: $1.04B
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 7077% more annual revenue ($56.58B vs $788.37M). NVS leads profitability with a 23.9% profit margin vs -13.1%. EVO appears more attractively valued with a PEG of 1.42. NVS earns a higher WallStSmart Score of 51/100 (C-).
EVO
Hold43
out of 100
Grade: D
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for EVO.
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -11.7% — below average capital efficiency
Distress zone — elevated risk
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : EVO
The strongest argument for EVO centers on Price/Book. Revenue growth of 14.5% demonstrates continued momentum. PEG of 1.42 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : EVO
The primary concerns for EVO are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
EVO profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
EVO carries more volatility with a beta of 1.24 — expect wider price swings.
EVO is growing revenue faster at 14.5% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 43/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evotec SE ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evotec SE is a prominent global biotechnology firm headquartered in Hamburg, Germany, specializing in end-to-end drug discovery and development solutions for the pharmaceutical and biotech industries. The company employs a synergistic approach, collaborating with both established pharmaceutical giants and cutting-edge academic institutions to accelerate the advancement of a diverse range of therapeutic programs, including small molecules, biologics, and cell therapies. With a strong and growing pipeline of projects, Evotec is strategically positioned to leverage emerging opportunities in the biopharmaceutical landscape, reinforcing its essential role in driving healthcare innovation and improving patient outcomes.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?